U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H15ClF4N4O3
Molecular Weight 482.815
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of REGORAFENIB ANHYDROUS

SMILES

CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=C1

InChI

InChIKey=FNHKPVJBJVTLMP-UHFFFAOYSA-N
InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)

HIDE SMILES / InChI
Molecular Formula C21H15ClF4N4O3
Molecular Weight 482.815
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
123738
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:21:27 UTC 2023
Edited
by admin
on Fri Dec 15 17:21:27 UTC 2023
Record UNII
24T2A1DOYB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
REGORAFENIB ANHYDROUS
DASH   INN   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Common Name English
4-(4-(((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)CARBAMOYL)AMINO)-3-FLUOROPHENOXY)-N-METHYLPYRIDINE-2-CARBOXAMIDE
Systematic Name English
BAY 73-4506
Code English
Regorafenib [WHO-DD]
Common Name English
BAY-734506
Code English
REGORAFENIB [VANDF]
Common Name English
regorafenib [INN]
Common Name English
REGORAFENIB [MI]
Common Name English
BAY-73-4506
Code English
Classification Tree Code System Code
NCI_THESAURUS C1742
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
WHO-ATC L01XE21
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
FDA ORPHAN DRUG 329410
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
NCI_THESAURUS C1404
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
NCI_THESAURUS C129825
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
LIVERTOX 839
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
EMA ASSESSMENT REPORTS STIVARGA (AUTHORIZED: COLORECTAL NEOPLASMS)
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
FDA ORPHAN DRUG 690619
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
NDF-RT N0000175605
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
WHO-VATC QL01XE21
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
FDA ORPHAN DRUG 478015
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
Code System Code Type Description
SMS_ID
100000136039
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
CHEBI
68647
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
WIKIPEDIA
Regorafenib
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
CAS
755037-03-7
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
IUPHAR
5891
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
DRUG BANK
DB08896
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
FDA UNII
24T2A1DOYB
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
DAILYMED
24T2A1DOYB
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
LACTMED
Regorafenib
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
DRUG CENTRAL
4654
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
CHEBI
68646
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
EVMPD
SUB73090
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
NCI_THESAURUS
C78204
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
PUBCHEM
11167602
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
RXCUI
1312397
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1946170
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
MERCK INDEX
m11701
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
EPA CompTox
DTXSID60226441
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
MESH
C559147
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
NDF-RT
N0000185504
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY Cytochrome P450 2C9 Inhibitors [MoA]
INN
9026
Created by admin on Fri Dec 15 17:21:27 UTC 2023 , Edited by admin on Fri Dec 15 17:21:27 UTC 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 2B6
METABOLIC ENZYME -> INHIBITOR
Ki
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2
TARGET -> INHIBITOR
OATP-8
TRANSPORTER -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
METABOLIC ENZYME -> INHIBITOR
SN-38 is metabolized by UGT1A1, it appears that regorafenib inhibits UGT1A1 in humans. The mean AUC of irinotecan and SN-38 increased by 28% and 44%, respectively, when irinotecan was administered five days after the last of seven daily doses of regorafenib.
Structure of REGORAFENIB
SOLVATE->ANHYDROUS
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> INHIBITOR
Regorafenib inhibits BCRP in vitro.
IC50
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> INHIBITOR
Regorafenib inhibits Pgp and BCRP in vitro.
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A9
METABOLIC ENZYME -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
CYTOCHROME P450 2C19
METABOLIC ENZYME -> INHIBITOR
Ki
SERINE/THREONINE-PROTEIN KINASE B-RAF V600E
TARGET -> INHIBITOR
ANGIOPOIETIN-1 RECEPTOR
TARGET -> INHIBITOR
CYTOCHROME P450 2C9
METABOLIC ENZYME -> INHIBITOR
Ki
CYTOCHROME P450 2C8
METABOLIC ENZYME -> INHIBITOR
Ki
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
Ki
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MITOGEN-ACTIVATED PROTEIN KINASE 11
TARGET -> INHIBITOR
SERINE/THREONINE-PROTEIN KINASE B-RAF
TARGET -> INHIBITOR
Structure of REGORAFENIB ANHYDROUS
EXCRETED UNCHANGED
FECAL
Structure of REGORAFENIB
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 4-(4-((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)CARBAMOYLAMINO)-3-FLUORO-PHENOXY)-N-(HYDROXYMETHYL)-1-OXIDO-PYRIDIN-1-IUM-2-CARBOXAMIDE
METABOLITE INACTIVE -> PARENT
Structure of BAY-751098
METABOLITE INACTIVE -> PARENT
Structure of 4-(4-((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)CARBAMOYLAMINO)-3-FLUORO-PHENOXY)PYRIDINE-2-CARBOXYLIC ACID
METABOLITE INACTIVE -> PARENT
Structure of N-DESMETHYL REGORAFENIB N-OXIDE
METABOLITE ACTIVE -> PARENT
AT STEADY STATE
MAJOR
PLASMA
Structure of BAY-757495
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
Structure of 1-((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)(((2-FLUORO-4-((2-((METHYLAMINO)CARBONYL)-1-OXIDO-4-PYRIDINYL)OXY)PHENYL)AMINO)CARBONYL)AMINO)-1-DEOXY-.BETA.-D-GLUCOPYRANURONIC ACID
METABOLITE INACTIVE -> PARENT
FECAL
Structure of REGORAFENIB METABOLITE M7
METABOLITE INACTIVE -> PARENT
MAJOR
FECAL
Related Record Type Details
Structure of REGORAFENIB ANHYDROUS
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC SINGLE DOSE

Cmax PHARMACOKINETIC
Tmax PHARMACOKINETIC SINGLE DOSE

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966